Current research activities include clinical trials of new and improved vaccines for children and adults, surveillance of invasive bacterial diseases and penumococcal vaccine impact in children in Nepal, studies of cellular and humoral immune responses to glycoconjugate and typhoid vaccines, and development of a serogroup B meningococcal vaccine.
ANDREW J POLLARD, FRCPCH PhD FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford, Director of the Oxford Vaccine Group, Fellow of St Cross College and Honorary Consultant Paediatrician at the Children’s Hospital, Oxford, UK. He obtained his medical degree at St Bartholomew’s Hospital Medical School, University of London in 1989 and trained in Paediatrics at Birmingham Children’s Hospital, UK, specialising in Paediatric Infectious Diseases at St Mary’s Hospital, London, UK and at British Columbia Children’s Hospital, Vancouver, Canada. He obtained his PhD at St Mary’s Hospital, London, UK in 199
Britain is winning its war against Covid and the success of the vaccination campaign would have been ‘unthinkable’ a year ago, the Oxford vaccine chief said yesterday.
Professor Andrew Pollard predicted jabs to tackle new variants of the virus could be ready as early as September.
But even the existing vaccines would provide some protection against these strains, he said, emphasising that the pandemic simply would not be as ‘hot’ compared with the past few months.
In an interview marking the one-year anniversary of the first person in Europe being given a Covid jab as part of the Oxford trial, he said vaccines were ‘the way out’ of never-ending lockdowns.
18 February 2021
4 research studies funded to better understand and address the longer-term effects of COVID on physical and mental health
Approximately 1 in 10 people with COVID-19 continue to experience symptoms beyond 12 weeks
Government funding for the projects approved in partnership with the National Institute for Health Research (
NIHR) and UK Research and Innovation (
UKRI)
People experiencing the longer-term effects of long COVID will benefit from £18.5 million to fund research projects to help better understand the causes, symptoms and treatment of the condition.
The funding will be given to 4 studies to identify the causes of long COVID and effective therapies to treat people who experience chronic symptoms of the disease.